CDC/IDSA COVID-19 Clinician Call February 27, 2021

Welcome & Introductions

Dana Wollins, DrPH, MGC

Vice President, Clinical Affairs & Guidelines

IDSA

- 56th in a series of weekly calls, initiated by CDC as a forum for information sharing among frontline clinicians caring for patients with COVID-19
- The views and opinions expressed here are those of the presenters and do not necessarily reflect the official policy or position of the CDC or IDSA. Involvement of CDC and IDSA should not be viewed as endorsement of any entity or individual involved.
- This webinar is being recorded and can be found online at www.idsociety.org/cliniciancalls.

CDC-IDSA Partnership: Clinical Management Call Support

FOR WHOM?


Clinicians who have questions about the clinical management of COVID-19

WHAT?

- Calls from clinicians will be triaged by CDC to a group of IDSA volunteer clinicians for peer-to-peer support

HOW?

- Clinicians may call the main CDC information line at 800-CDC-INFO (800-232-4636)
- To submit your question in writing, go to www.cdc.gov/cdc-info and click on Contact Form







Now Available: COVID-19 Vaccine FAQs


Go to www.COVID19LearningNetwork.org and click on "Vaccines FAQ"

CDC Would Like Your Input: Re-use of N95s

Today's Topic

Johnson & Johnson/ Janssen Biotech, Inc. COVID-19 Vaccine EUA: What You Need to Know

COVID-19 Vaccine in the United States



Johnson & Johnson / Janssen Biotech, Inc. COVID-19 Vaccine EUA - What You Need to Know



Archana Chatterjee, MD, PhD
Dean, Chicago Medical School
Vice President for Medical Affairs

Member, Vaccines & Related Biological Products Advisory Committee, Food and Drug Administration



Hana M. El Sahly, MD

Rosalind Franklin University

Associate Professor of Molecular Virology and Microbiology Baylor College of Medicine

Chair, Vaccines & Related Biological Products Advisory Committee, Food and Drug Administration



Amanda Cohn, MD

Chief Medical Officer, National Center for Immunization & Respiratory Diseases
Chief Medical Officer, COVID-19 Vaccine Task Force
CAPT, US Public Health Service
Centers for Disease Control and Prevention

Member, Vaccines & Related Biological Products Advisory Committee Food and Drug Administration

Disclosures

Hana M. El Sahly, MD

Received NIH funding as co-PI of P301, the Phase 3 study evaluating the efficacy of mRNA1273 (Moderna vaccine)

Archana Chatterjee, MD, PhD

Nothing to disclose.

Amanda Cohn, MD


Nothing to disclose.

Question? Use the "Q&A" Button





Comment?
Use the "Chat" Button



The Vaccine and Related Biological Products Adivsory Committee Meeting 26Feb21

Summary of Discussion Points

Ad26.CoV2.S to prevent COVID-19

- Immune Response to the Vaccine
- 1. Is the vector eliciting innate immune responses?
- 2. Role of pre-existing vector immunity on the vaccine's immunogenicity
- 3. Role of de novo vector immunity on responsiveness to future doses of the vaccine
- 4. Correlates of Protection

Ad26.CoV2.S to prevent COVID-19

- Vaccine in special populations:
- Adolescents
- 2. Children
- 3. Immunocompromised
- Role of a second dose of Ad26.CoV2.S
- 1. Under Evaluation in a Phase 3 clinical trial
- 2. What if the efficacy of a single dose wanes over time/with variants and a second dose is needed.

Ad26.CoV2.S to prevent COVID-19

- Efficacy in elderly (60yo or older) with underlying comorbidities
- 1. VE of 42% (-13,11%-71.6%)
- 2. Phase 1/2 study data: vaccine is immunogenic in this group

MEETING OF THE ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES (ACIP)

Centers for Disease Control and Prevention

Atlanta, Georgia 30329

February 28 and March 1, 2021

A	GENDA ITEM	PRESIDER/PRESENTER(s)
Sunday, February 28, 2021		
11:00	Welcome & Introductions	Dr. José Romero (ACIP Chair)
		Dr. Amanda Cohn (ACIP Executive Secretary, CDC)
11:15	Coronavirus Disease 2019 (COVID-19) Vaccines	
	Introduction	Dr. Beth Bell (ACIP, WG Chair)
	Ad.26.COV2.S Development Program	TBD
12:30	Break	
12:45	GRADE: Janssen COVID-19 vaccine	Dr. Julia Gargano (CDC/NCIRD)
	Evidence to Recommendation Framework: Janssen COVID-19 vaccine	Dr. Sara Oliver (CDC/NCIRD)
2:00	Break	
2:15	Public Comment	
3:00	Discussion	
	<u>VOTE</u>	
	Janssen COVID-19 Vaccine	Dr. Sara Oliver (CDC/NCIRD)
4:00	Adjourn	

MEETING OF THE ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES (ACIP)

Centers for Disease Control and Prevention Atlanta, Georgia 30329 February 28 and March 1, 2021

Monday, March 1, 2021		rch 1, 2021	PRESIDER/PRESENTER(s)	
	11:00	Welcome & Introductions	Dr. José Romero (ACIP Chair)	
			Dr. Amanda Cohn (ACIP Executive Secretary, CDC)	
	11:15	Coronavirus Disease 2019 (COVID-19) Vaccines		
		Introduction	Dr. Beth Bell (ACIP, WG Chair)	
		Implementation considerations for COVID-19 vaccines	Dr. Kathleen Dooling (CDC/NCIRD)	
		Clinical Considerations for use of COVID-19 vaccines	Ms. Jessica MacNeil (CDC/NCIRD)	
	12:30	Break		
	1:00	Vaccine Safety Technical Subgroup (VaST) introduction	Dr. Grace Lee (ACIP, VaST Co-chair)	
		COVID-19 Vaccine Safety Update	Dr. Tom Shimabukuro (CDC/NCEZID)	
		VaST assessement of safety data	Dr. Grace Lee (ACIP, VaST Co-chair)	
	2:00	Break		
	2:15	Emerging SARS-CoV-2 Variants	Dr. Heather Scobie (CDC/CGH)	
	3:00	Adjourn		

Continue the conversation on Twitter

@RealTimeCOVID19
#RealTimeCOVID19



We want to hear from you! Please complete the post-call survey.

Next Call: Saturday, Mar. 6th

A recording of this call will be posted at www.idsociety.org/cliniciancalls

-- library of all past calls now available --

Contact Us:

Dana Wollins (dwollins@idsociety.org)

Deirdre Lewis (dlewis@idsociety.org)